Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 98

1.

OXA1L mutations cause mitochondrial encephalopathy and a combined oxidative phosphorylation defect.

Thompson K, Mai N, Oláhová M, Scialó F, Formosa LE, Stroud DA, Garrett M, Lax NZ, Robertson FM, Jou C, Nascimento A, Ortez C, Jimenez-Mallebrera C, Hardy SA, He L, Brown GK, Marttinen P, McFarland R, Sanz A, Battersby BJ, Bonnen PE, Ryan MT, Chrzanowska-Lightowlers ZM, Lightowlers RN, Taylor RW.

EMBO Mol Med. 2018 Nov;10(11). pii: e9060. doi: 10.15252/emmm.201809060.

2.

Sternoclavicular joint replacement case report.

Robertson FM, Mohammed AA, Frostick SP.

J Orthop Surg (Hong Kong). 2018 Jan-Apr;26(1):2309499018761176. doi: 10.1177/2309499018761176.

PMID:
29529953
3.

Lineage-specific rediploidization is a mechanism to explain time-lags between genome duplication and evolutionary diversification.

Robertson FM, Gundappa MK, Grammes F, Hvidsten TR, Redmond AK, Lien S, Martin SAM, Holland PWH, Sandve SR, Macqueen DJ.

Genome Biol. 2017 Jun 14;18(1):111. doi: 10.1186/s13059-017-1241-z.

4.

Targeting SH2 domains in breast cancer.

Morlacchi P, Robertson FM, Klostergaard J, McMurray JS.

Future Med Chem. 2014;6(17):1909-26. doi: 10.4155/fmc.14.120. Review.

5.

Potent inhibition by ropivacaine of metastatic colon cancer SW620 cell invasion and NaV1.5 channel function.

Baptista-Hon DT, Robertson FM, Robertson GB, Owen SJ, Rogers GW, Lydon EL, Lee NH, Hales TG.

Br J Anaesth. 2014 Jul;113 Suppl 1:i39-i48. doi: 10.1093/bja/aeu104. Epub 2014 May 22.

6.

The class I HDAC inhibitor Romidepsin targets inflammatory breast cancer tumor emboli and synergizes with paclitaxel to inhibit metastasis.

Robertson FM, Chu K, Boley KM, Ye Z, Liu H, Wright MC, Moraes R, Zhang X, Green TL, Barsky SH, Heise C, Cristofanilli M.

J Exp Ther Oncol. 2013;10(3):219-33.

PMID:
24416998
7.

Gene expression profiles of inflammatory breast cancer: correlation with response to neoadjuvant chemotherapy and metastasis-free survival.

Bertucci F, Ueno NT, Finetti P, Vermeulen P, Lucci A, Robertson FM, Marsan M, Iwamoto T, Krishnamurthy S, Masuda H, Van Dam P, Woodward WA, Cristofanilli M, Reuben JM, Dirix L, Viens P, Symmans WF, Birnbaum D, Van Laere SJ.

Ann Oncol. 2014 Feb;25(2):358-65. doi: 10.1093/annonc/mdt496. Epub 2013 Dec 2.

8.

Presence of anaplastic lymphoma kinase in inflammatory breast cancer.

Robertson FM, Petricoin Iii EF, Van Laere SJ, Bertucci F, Chu K, Fernandez SV, Mu Z, Alpaugh K, Pei J, Circo R, Wulfkuhle J, Ye Z, Boley KM, Liu H, Moraes R, Zhang X, Demaria R, Barsky SH, Sun G, Cristofanilli M.

Springerplus. 2013 Oct 1;2:497. doi: 10.1186/2193-1801-2-497. eCollection 2013.

9.
10.

Inflammatory breast cancer (IBC): clues for targeted therapies.

Fernandez SV, Robertson FM, Pei J, Aburto-Chumpitaz L, Mu Z, Chu K, Alpaugh RK, Huang Y, Cao Y, Ye Z, Cai KQ, Boley KM, Klein-Szanto AJ, Devarajan K, Addya S, Cristofanilli M.

Breast Cancer Res Treat. 2013 Jul;140(1):23-33. doi: 10.1007/s10549-013-2600-4. Epub 2013 Jun 21.

11.
12.

Uncovering the molecular secrets of inflammatory breast cancer biology: an integrated analysis of three distinct affymetrix gene expression datasets.

Van Laere SJ, Ueno NT, Finetti P, Vermeulen P, Lucci A, Robertson FM, Marsan M, Iwamoto T, Krishnamurthy S, Masuda H, van Dam P, Woodward WA, Viens P, Cristofanilli M, Birnbaum D, Dirix L, Reuben JM, Bertucci F.

Clin Cancer Res. 2013 Sep 1;19(17):4685-96. doi: 10.1158/1078-0432.CCR-12-2549. Epub 2013 Feb 8.

13.

A phosphopeptide mimetic prodrug targeting the SH2 domain of Stat3 inhibits tumor growth and angiogenesis.

Auzenne EJ, Klostergaard J, Mandal PK, Liao WS, Lu Z, Gao F, Bast RC Jr, Robertson FM, McMurray JS.

J Exp Ther Oncol. 2012;10(2):155-62.

14.

Early to intermediate steps of tumor embolic formation involve specific proteolytic processing of E-cadherin regulated by Rab7.

Ye Y, Gao JX, Tian H, Yearsley K, Lange AR, Robertson FM, Barsky SH.

Mol Cancer Res. 2012 Jun;10(6):713-26. doi: 10.1158/1541-7786.MCR-12-0009. Epub 2012 May 25.

15.

The genesis and unique properties of the lymphovascular tumor embolus are because of calpain-regulated proteolysis of E-cadherin.

Ye Y, Tian H, Lange AR, Yearsley K, Robertson FM, Barsky SH.

Oncogene. 2013 Mar 28;32(13):1702-13. doi: 10.1038/onc.2012.180. Epub 2012 May 14.

PMID:
22580607
16.

Pre-clinical studies of Notch signaling inhibitor RO4929097 in inflammatory breast cancer cells.

Debeb BG, Cohen EN, Boley K, Freiter EM, Li L, Robertson FM, Reuben JM, Cristofanilli M, Buchholz TA, Woodward WA.

Breast Cancer Res Treat. 2012 Jul;134(2):495-510. doi: 10.1007/s10549-012-2075-8. Epub 2012 May 1.

17.

Efficient synthesis of apricoxib, CS-706, a selective cyclooxygenase-2 inhibitor, and evaluation of inhibition of prostaglandin E2 production in inflammatory breast cancer cells.

Mandal PK, Freiter EM, Bagsby AL, Robertson FM, McMurray JS.

Bioorg Med Chem Lett. 2011 Oct 15;21(20):6071-3. doi: 10.1016/j.bmcl.2011.08.050. Epub 2011 Aug 19.

18.

A global approach to inflammatory breast cancer.

Robertson FM, Cristofanilli M.

Future Oncol. 2011 Jan;7(1):25-30. doi: 10.2217/fon.10.177.

19.

Inflammatory breast cancer: the disease, the biology, the treatment.

Robertson FM, Bondy M, Yang W, Yamauchi H, Wiggins S, Kamrudin S, Krishnamurthy S, Le-Petross H, Bidaut L, Player AN, Barsky SH, Woodward WA, Buchholz T, Lucci A, Ueno NT, Cristofanilli M.

CA Cancer J Clin. 2010 Nov-Dec;60(6):351-75. doi: 10.3322/caac.20082. Epub 2010 Oct 19. Review. Erratum in: CA Cancer J Clin. 2011 Mar-Apr;61(2):134. Ueno, Naoto [corrected to Ueno, Naoto T].

20.

Toxicological and pathophysiological roles of reactive oxygen and nitrogen species.

Roberts RA, Smith RA, Safe S, Szabo C, Tjalkens RB, Robertson FM.

Toxicology. 2010 Oct 9;276(2):85-94. doi: 10.1016/j.tox.2010.07.009. Epub 2010 Jul 17. Review. Erratum in: Toxicology. 2011 Jan 11;279(1-3):208.

PMID:
20643181
21.

Imaging and analysis of 3D tumor spheroids enriched for a cancer stem cell phenotype.

Robertson FM, Ogasawara MA, Ye Z, Chu K, Pickei R, Debeb BG, Woodward WA, Hittelman WN, Cristofanilli M, Barsky SH.

J Biomol Screen. 2010 Aug;15(7):820-9. doi: 10.1177/1087057110376541. Epub 2010 Jul 16.

PMID:
20639504
22.

International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment.

Dawood S, Merajver SD, Viens P, Vermeulen PB, Swain SM, Buchholz TA, Dirix LY, Levine PH, Lucci A, Krishnamurthy S, Robertson FM, Woodward WA, Yang WT, Ueno NT, Cristofanilli M.

Ann Oncol. 2011 Mar;22(3):515-23. doi: 10.1093/annonc/mdq345. Epub 2010 Jul 5.

23.

Differential regulation of the aggressive phenotype of inflammatory breast cancer cells by prostanoid receptors EP3 and EP4.

Robertson FM, Simeone AM, Lucci A, McMurray JS, Ghosh S, Cristofanilli M.

Cancer. 2010 Jun 1;116(11 Suppl):2806-14. doi: 10.1002/cncr.25167.

24.

Suberoylanilide hydroxamic acid blocks self-renewal and homotypic aggregation of inflammatory breast cancer spheroids.

Robertson FM, Woodward WA, Pickei R, Ye Z, Bornmann W, Pal A, Peng Z, Hall CS, Cristofanilli M.

Cancer. 2010 Jun 1;116(11 Suppl):2760-7. doi: 10.1002/cncr.25176.

25.
26.

Nitrative and oxidative stress in toxicology and disease.

Roberts RA, Laskin DL, Smith CV, Robertson FM, Allen EM, Doorn JA, Slikker W.

Toxicol Sci. 2009 Nov;112(1):4-16. doi: 10.1093/toxsci/kfp179. Epub 2009 Aug 5. Review.

27.

Molecular and pharmacological blockade of the EP4 receptor selectively inhibits both proliferation and invasion of human inflammatory breast cancer cells.

Robertson FM, Simeone AM, Mazumdar A, Shah AH, McMurray JS, Ghosh S, Cristofanilli M.

J Exp Ther Oncol. 2008;7(4):299-312.

PMID:
19227010
28.

Nanotechnology for breast cancer therapy.

Tanaka T, Decuzzi P, Cristofanilli M, Sakamoto JH, Tasciotti E, Robertson FM, Ferrari M.

Biomed Microdevices. 2009 Feb;11(1):49-63. doi: 10.1007/s10544-008-9209-0. Review.

PMID:
18663578
29.

Cyclooxygenase-2 directly induces MCF-7 breast tumor cells to develop into exponentially growing, highly angiogenic and regionally invasive human ductal carcinoma xenografts.

Robertson FM, Mallery SR, Bergdall-Costell VK, Cheng M, Pei P, Prosperi JR, Ferrari M.

Anticancer Res. 2007 Mar-Apr;27(2):719-27.

30.
31.

Activation of Akt and mTOR in CD34+/K15+ keratinocyte stem cells and skin tumors during multi-stage mouse skin carcinogenesis.

Affara NI, Trempus CS, Schanbacher BL, Pei P, Mallery SR, Bauer JA, Robertson FM.

Anticancer Res. 2006 Jul-Aug;26(4B):2805-20.

32.

Management of perinatal torsion: today, tomorrow or never?

Yerkes EB, Robertson FM, Gitlin J, Kaefer M, Cain MP, Rink RC.

J Urol. 2005 Oct;174(4 Pt 2):1579-82; discussion 1582-3.

PMID:
16148656
33.

Vascular endothelial growth factor as a survival factor in tumor-associated angiogenesis.

Affara NI, Robertson FM.

In Vivo. 2004 Sep-Oct;18(5):525-42. Review.

34.

Activated Akt-1 in specific cell populations during multi-stage skin carcinogenesis.

Affara NI, Schanbacher BL, Mihm MJ, Cook AC, Pei P, Mallery SR, Trempus CS, Bauer JA, Robertson FM.

Anticancer Res. 2004 Sep-Oct;24(5A):2773-81.

35.

Invasive and angiogenic phenotype of MCF-7 human breast tumor cells expressing human cyclooxygenase-2.

Prosperi JR, Mallery SR, Kigerl KA, Erfurt AA, Robertson FM.

Prostaglandins Other Lipid Mediat. 2004 Apr;73(3-4):249-64.

PMID:
15290792
36.

Implications for oxidative and nitrative stress in the pathogenesis of AIDS-related Kaposi's sarcoma.

Mallery SR, Pei P, Landwehr DJ, Clark CM, Bradburn JE, Ness GM, Robertson FM.

Carcinogenesis. 2004 Apr;25(4):597-603. Epub 2003 Dec 4.

37.

Endostatin inhibits migration and invasion of head and neck squamous cell carcinoma cells.

Wilson RF, Morse MA, Pei P, Renner RJ, Schuller DE, Robertson FM, Mallery SR.

Anticancer Res. 2003 Mar-Apr;23(2B):1289-95.

PMID:
12820385
38.
39.

AIDS-related Kaposi's sarcoma cells rapidly internalize endostatin, which co-localizes to tropomysin microfilaments and inhibits cytokine-mediated migration and invasion.

Mallery SR, Morse MA, Wilson RF, Pei P, Ness GM, Bradburn JE, Renner RJ, Schuller DE, Robertson FM.

J Cell Biochem. 2003 May 1;89(1):133-43.

PMID:
12682914
40.

Inhibition of ultraviolet light B-induced cutaneous inflammation by a specific cyclooxygenase-2 inhibitor.

Wilgus TA, Parrett ML, Ross MS, Tober KL, Robertson FM, Oberyszyn TM.

Adv Exp Med Biol. 2002;507:85-92.

PMID:
12664569
41.

Protection of human keratinocyte mtDNA by low-level nitric oxide.

Shokolenko I, Oberyszyn TM, D'Ambrosio SM, Saavedra JE, Keefer LK, LeDoux SP, Wilson GL, Robertson FM.

Nitric Oxide. 2001 Dec;5(6):555-60.

PMID:
11730362
42.

Inhibition of cutaneous UV light-induced tumor necrosis factor-alpha protein production by Allotrap 1258, a novel immunomodulatory peptide.

Oberyszyn TM, Robertson FM, Tober KL, Ross MS, Parrett ML, Wilgus TA, Iyer S, Woo J, Buelow R.

Photochem Photobiol. 2001 Feb;73(2):184-90.

PMID:
11272733
43.

Mechanisms of nitric oxide-induced cytotoxicity in normal human hepatocytes.

D'Ambrosio SM, Gibson-D'Ambrosio RE, Brady T, Oberyszyn AS, Robertson FM.

Environ Mol Mutagen. 2001;37(1):46-54.

PMID:
11170241
45.

Laparoscopic nephrectomy in children.

York GB, Robertson FM, Cofer BR, Bomalaski MD, Lynch SC.

Surg Endosc. 2000 May;14(5):469-72.

PMID:
10858474
46.
47.

Comparative chemopreventive activity of ibuprofen and N-(4-hydroxyphenyl) retinamide against the development and growth of rat mammary adenocarcinomas.

Alshafie GA, Harris RE, Robertson FM, Parrett ML, Ross M, Abou-Issa H.

Anticancer Res. 1999 Jul-Aug;19(4B):3031-6.

PMID:
10652588
48.

Genetic induction and upregulation of cyclooxygenase (COX) and aromatase (CYP19): an extension of the dietary fat hypothesis of breast cancer.

Harris RE, Robertson FM, Abou-Issa HM, Farrar WB, Brueggemeier R.

Med Hypotheses. 1999 Apr;52(4):291-2.

PMID:
10465664
49.

Correlation of aromatase and cyclooxygenase gene expression in human breast cancer specimens.

Brueggemeier RW, Quinn AL, Parrett ML, Joarder FS, Harris RE, Robertson FM.

Cancer Lett. 1999 Jun 1;140(1-2):27-35.

PMID:
10403538
50.

Comparative expression of novel vascular endothelial growth factor/vascular permeability factor transcripts in skin, papillomas, and carcinomas of v-Ha-ras Tg.AC transgenic mice and FVB/N mice.

Tober KL, Cannon RE, Spalding JW, Oberyszyn TM, Parrett ML, Rackoff AI, Oberyszyn AS, Tennant RW, Robertson FM.

Biochem Biophys Res Commun. 1998 Jun 29;247(3):644-53.

PMID:
9647747

Supplemental Content

Loading ...
Support Center